PATENT CLAIM ANALYSIS

Application Number: 16260360
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "405000"]

Abstract:
Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

Claim (Index 1):
A method of treating a subject hosting a non-ACTH-secreting pancreatic tumor, the method comprising a combination treatment comprising a) administering to the subject an anticancer treatment selected from surgery, radiation treatment, immunotherapy administration, growth factor inhibitor administration, and administration of an anti-angiogenesis factor; b) administering to the subject an effective amount of a chemotherapeutic agent; and c) administering to the subject an effective amount of a nonsteroidal selective glucocorticoid receptor modulator to reduce the tumor load of the pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising a fused azadecalin structure having the formula: wherein L 1  and L 2  are members independently selected from a bond and unsubstituted alkylene; R 1  is a member selected from unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, \u2014OR 1A , NR 1C R 1D , \u2014C(O)NR 1C R 1D , and \u2014C(O)OR 1A , wherein R 1A  is a member selected from hydrogen, unsubstituted alkyl and unsubstituted heteroalkyl, R 1C  and R 1D  are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl, wherein R 1C  and R 1D  are optionally joined to form an unsubstituted ring with the nitrogen to which they are attached, wherein said ring optionally comprises an additional ring nitrogen; R 2  has the formula: wherein R 2G  is a member selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, \u2014CN, and \u2014CF  3 ; J is phenyl; t is an integer from 0 to 5; X is \u2014S(O 2 )\u2014; and R 5  is phenyl optionally substituted with 1-5 R 5A  groups, wherein R 5A  is a member selected from hydrogen, halogen, \u2014OR 5A1 , S(O 2 )NR 5A2 R 5A3 , \u2014CN, and unsubstituted alkyl, wherein R 5A1  is a member selected from hydrogen and unsubstituted alkyl, and R 5A2  and R 5A3  are members independently selected from hydrogen and unsubstituted alkyl, or salts and isomers thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 99.0
- Lexical Diversity: 3.01786
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15915477', '16150916', '15697878', '16185271', '15942312']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8617554935937433
- 35 USC 102 Novelty (BERT): 0.6670033668758436
- Combined Prediction Score: 0.8422802809219533
- Mean Citation Score: 659.3482640000002
- Max Citation Score: 726.39886
- Similarity Product: 631.2094052019596

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test